NDAQ
50
-6
CHRW
51
-6
SLG
57
4
UNH
44
2
MU
42
7
SPG
53
2
PHM
53
-4
FTI
76
3
CRM
72
-3
JBHT
53
-3
CSCO
61
-3
A
39
-2
FCX
50
-2
FLS
69
-2
AVB
57
-2
TROW
50
2
EW
53
-2
ROK
52
-2
CMG
69
-4
XEL
53
-2
NDAQ
50
-6
CHRW
51
-6
SLG
57
4
UNH
44
2
MU
42
7
SPG
53
2
PHM
53
-4
FTI
76
3
CRM
72
-3
JBHT
53
-3
CSCO
61
-3
A
39
-2
FCX
50
-2
FLS
69
-2
AVB
57
-2
TROW
50
2
EW
53
-2
ROK
52
-2
CMG
69
-4
XEL
53
-2
Financhill
Back

Cyclo Therapeutics 10K Form

Sell
31

CYTH
Cyclo Therapeutics

Last Price:
0.59
Seasonality Move:
18.97%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CYTH News And Ratings

See the #1 stock for the next 7 days that we like better than CYTH

CYTH Financial Statistics

Sales & Book Value

Annual Sales: $1.08M
Cash Flow: $-8.19M
Price / Cash Flow: 0
Annual Sales: $-0.47
Price / Book: 0

Profitability

EPS (TTM): -0.90000
Net Income (TTM): $-24.8M
Gross Margin: $992.04K
Return on Equity: 0%
Return on Assets: -344.63%

Cyclo Therapeutics Earnings Forecast

Key Cyclo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 24 years for CYTH is 92.16%.
  • The Selling, General & Administrative Expenses for CYTH have been equal to 526.37% of Gross Profit Margin.
  • The Research & Development expenses have been 1,317.51% of Revenue.
  • The Interest Expense is -0.68% of Operating Income.
  • The Net Earning history of CYTH is -1,863.35% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 14 years.

Cyclo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CYTH
Website: cyclotherapeutics.com

Debt

Debt-to-Equity Ratio: -0.9
Current Ratio: 0.17
Quick Ratio: 0.06

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYTH Technical Analysis vs Fundamental Analysis

Sell
31
Cyclo Therapeutics (CYTH) is a Sell

Is Cyclo Therapeutics a Buy or a Sell?